The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.
about
Prevalence, clinical and virologic outcomes of hepatitis B virus co-infection in HIV-1 positive Kenyan women on antiretroviral therapyDifferences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).Classifying genotype F of hepatitis B virus into F1 and F2 subtypes.Novel hepatitis B virus genotype a subtyping assay that distinguishes subtype Aa from Ae and its application in epidemiological studies.Clinical characteristics and distribution of hepatitis B virus genotypes in Guangxi Zhuang population.Early detection of hepatitis B drug resistance: implications for patient management.Molecular virology in chronic hepatitis B: genotypes.Recent developments in the diagnosis and monitoring of HBV infection and role of the genetic variability of the S gene.Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2.Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment.Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy.Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China.Therapeutic implications of hepatitis B virus genotypes.A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine.Antiviral therapies: focus on hepatitis B reverse transcriptaseMolecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China.Future prospectives for the management of chronic hepatitis B.Molecular testing in the diagnosis and management of chronic hepatitis BDistribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A.Hepatitis B virus genotypes: natural history and implications for treatment.Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares.Virological and Clinical Characteristics of Hepatitis B Virus Genotype A.Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors.Effect of hepatitis B virus subgenotype on antiviral response in nucleoside-treated hepatitis B envelope antigen-positive patients.JSH Guidelines for the Management of Hepatitis B Virus Infection.Hepatitis B virus genotyping among chronic hepatitis B patients with resistance to treatment with lamivudine in the City of Ribeirão Preto, State of São Paulo.Distribution and characteristics of hepatitis B virus genotype C subgenotypes in China.Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B.Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus.Interferon and lamivudine monotherapy on chronic hepatitis B in Japan.Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase.Hepatitis B virus genotypes and G1896A precore mutation in 486 Spanish patients with acute and chronic HBV infection.Virological differences between patients infected with subtypes Ba and Bj of hepatitis B virus genotype B.Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment.Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B.
P2860
Q28488149-2B22C924-E2B6-4DF7-A501-998AA7AD8859Q34700034-6CCF0E68-F574-4E70-B62F-1902F080C07DQ34719476-DA478E60-C99D-4873-A855-58C45E83AB32Q35059546-5C532081-2EDF-41DE-8E5B-35147A9DF9DAQ35123569-7DB54BA5-0FAF-4164-ACFC-35260EE6510EQ35165998-09A47FFF-D9DA-4769-9DD1-8F49D13A2F19Q35543876-A96F9360-E610-4AD4-A16A-20B3372B83DCQ36027130-89473A28-DC62-4902-BB9F-1C884B52B480Q36050544-B8CFD5B8-7A28-46F7-B7BA-563C9D5E3A17Q36098721-378DEF63-A0F5-486D-AF3D-579806FC8C05Q36177722-1C2CB556-DE41-4254-B023-4334DCAD60D0Q36180475-066BFEA5-32F3-4B32-9214-371291E029E3Q36234130-CCCCED4E-DE66-4906-95D6-36495732EF04Q36324370-5A8A36B0-9617-4C05-976E-910CD77206D6Q36338675-85229DC0-367D-4C03-B59E-5491B82797C0Q36445386-E0F337BE-4C49-4222-987B-52C3E87BC4E6Q36467514-A907C8B7-6697-493F-84B8-0191E62C5D42Q36516176-74740214-A6D5-4A6E-A5D3-6AC0A01C8EDEQ36841719-9F2D2A3E-8426-4658-B1E8-3D5FEDA0AF89Q36881140-BB236EA6-B4C0-4AD0-910B-02ACA464A984Q37191549-3BF38837-2F98-402B-8A5F-96F214E36243Q37346012-9BC77059-FA77-4413-9923-0D53FF99D8F3Q37511410-3ED27E91-FC87-4A3C-8D59-AC12D62E3063Q38661138-411D84B2-BB28-4AD8-985C-1F1BBF0B9FECQ40197893-F30B79D9-B3ED-468A-8CB6-707A204FA0ECQ40236925-7D18E580-1635-4D00-80C2-9650A2C5FDBBQ42244740-33DB7AF9-F150-457D-B704-AE630FA99603Q43012086-B71642C1-A75C-4141-82A5-D4EB0E9F2E91Q43037749-257827A7-0785-444F-8110-01B1E7C0F18AQ43427932-8E63475B-EB1B-4951-945E-5999625205F4Q45163318-EB16B2DD-32C2-4A2C-9530-B87E6D59C084Q45274836-B5B18C6C-F7BD-4CB1-AF4D-843E5E75E950Q45397929-82D36113-51F5-4183-938F-B38291D1ACC4Q45401215-337E113E-37E8-4162-8A9D-6870E3997B8FQ45417315-D642B110-12BA-430B-BC19-708D0483ABACQ45480055-DFB696EC-1CC4-4272-B829-B18BC4C39D9BQ46423677-C8618BC9-EEEF-472C-AD98-DF2DDC88C1DDQ46604917-FDF25BDB-FF67-4FB5-AB06-31F7113EDC9B
P2860
The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
The influence of hepatitis B v ...... ce during long-term treatment.
@en
type
label
The influence of hepatitis B v ...... ce during long-term treatment.
@en
prefLabel
The influence of hepatitis B v ...... ce during long-term treatment.
@en
P2093
P1476
The influence of hepatitis B v ...... nce during long-term treatment
@en
P2093
Akihito Tsubota
Fumitaka Suzuki
Hiromitsu Kumada
Kenji Ikeda
Mariko Kobayashi
Masahiro Kobayashi
Norio Akuta
Satoshi Saitoh
Takashi Someya
Yasuji Arase
P304
P356
10.1016/S0168-8278(02)00410-5
P577
2003-03-01T00:00:00Z